Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 8/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4386508 | 0.96 | PLA2G2A (0.40) | PLA2G2AFAAHPTGS2PTGDR2ALOX5AP | |
| SCHEMBL4099175 | 0.93 | ALOX5AP (0.38) | PLA2G2AFAAHMAPTALOX5APF2RL3 | |
| SCHEMBL4088892 | 0.92 | EPHX2 (0.40) | FAAHMAPTEPHX2 | |
| SCHEMBL3001872 | 0.91 | PLA2G2A (0.41) | PLA2G2AFAAHPTGS2PTGDR2F2RL3 | |
| SCHEMBL4099748 | 0.90 | FAAH (0.50) | PLA2G2AFAAHPTGS2MAPT | |
| SCHEMBL4090027 | 0.89 | FAAH (0.46) | FAAHPTGDR2MAPTEPHX2 | |
| SCHEMBL2992546 | 0.89 | PLA2G2A (0.43) | PLA2G2AFAAHPTGS2PTGDR2MAPT | |
| SCHEMBL3008127 | 0.89 | FAAH (0.44) | PLA2G2AFAAHPTGS2 | |
| SCHEMBL3001465 | 0.89 | PLA2G2A (0.44) | PLA2G2AFAAHPTGS2 | |
| SCHEMBL3008225 | 0.88 | PLA2G2A (0.45) | PLA2G2AFAAHPTGS2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2610244-A1 | Indole compounds | Ironwood Pharmaceuticals, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20090118503-A1 | FAAH INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118503-A1 | FAAH INHIBITORS | FAAH, FAAH2, CNR2 | PLA2G2A 242/4885FAAH 1/4885PTGS2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.